normative

FDA should design and run registration trials

Instead of the conflicted company designing, conducting, and reporting its own registration trial, the company should pay a much larger fee (e.g. $32-52 million instead of $2 million) and supply the drug, while the FDA or an impartial third party designs the control arm, population, post-protocol therapy, and statistical plan and runs the trial; once the Data and Safety Monitoring Board declares success, the drug is approved instantly with no back-end review, which removes the conflict, prevents gaming, and could even save a year of regulatory time.

normativepending

Speaker

Vinay Prasad

Evidence Quote

“the only definitive solution to... all the problems in cancer clinical trials, is to remove the conflicted players from the design and conduct”

Source

Vinay Prasad on Cancer Drugs, Medical Ethics, and Malignant— EconTalk
Created: 6/13/2026, 12:28:36 AM

Your notes

Loading notes...